Clinical trials: Retinal Disorders
Diabetic Macular Edema, Branch Retinal Vein Occlusion
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
- Conditions
- Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
- Trial name
- CLEAN (NCT05127525)
- Testing
- IRX-101, Control
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- iRenix Medical, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.
- Trial name
- NCT06701721
- Testing
- THN391
- Where
- 10 sites in Australia, Georgia
- Volunteers
- 21 people
- Sponsor
- Therini Bio Pty Ltd
Retinitis Pigmentosa
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP.
- Trial name
- NCT06912633
- Testing
- human retinal progenitor cells, Mock injection
- Where
- 12 sites in United States
- Volunteers
- 31 people
- Sponsor
- jCyte, Inc
Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular…
- Conditions
- Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
- Trial name
- NCT02599064
- Testing
- RXI-109
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- RXi Pharmaceuticals, Corp.
Age-Related Macular Degeneration
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
The purpose of the study is to evaluate the safety and efficacy of intravitreal (IVT) administration of DE-120 in subjects with treatment-naive active subfoveal choroidal neovascularization (CNV) secondary to age-related macular…
- Trial name
- VAPOR1 (NCT02401945)
- Testing
- DE-120, Aflibercept
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Santen Inc.
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
A Study of EXG102-031 in Patients With wAMD (Everest)
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage.
- Trial name
- NCT05903794
- Testing
- EXG102-031
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Exegenesis Bio
Diabetic Retinopathy
Treatment for Completers of the Study B7A-MC-MBCM
To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment.
- Trial name
- NCT00266695
- Testing
- Ruboxistaurin
- Where
- 29 sites in United States
- Volunteers
- 203 people
- Sponsor
- Chromaderm, Inc.
Assess Eye Measurements in Patients Having Retina Pathology or Glaucoma
Evaluation of OCT Measurements
The purpose of the study is to repeatability, reproducibility and agreement of eye measurements in retina and glaucoma patients.
- Trial name
- NCT01806402
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- Optovue
Central Serous Chorioretinopathy
Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy
The purpose of this clinical study is to evaluate the efficacy and safety of selective retina therapy (SRT) using R:GEN, an approved laser device, in patients with central serous chorioretinopathy.
- Trial name
- NCT03758963
- Testing
- R:GEN Selective Retina Therapy
- Where
- 6 sites in South Korea
- Volunteers
- 63 people
- Sponsor
- CynosureLutronic
Geographic Atrophy
Geographic Atrophy Long-Terms Outcomes Study
The purpose of this study is to describe functional and long-term clinical outcomes of patients with a diagnosis of Geographic Athrophy secondary to Age related Macular Degenaration in Clinical Practice
- Trial name
- GALTOS (NCT06499571)
- Where
- 5 sites in Australia, France and 3 more
- Volunteers
- 255 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Leber Congenital Amaurosis 10, Blindness
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
PQ-110-005 (BRIGHTEN) is an open-label, dose escalation and double-masked, randomized, controlled study evaluating safety and tolerability of sepofarsen administered via intravitreal (IVT) injection in pediatric subjects (<8…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders
- Trial name
- BRIGHTEN (NCT04855045)
- Testing
- sepofarsen
- Where
- 9 sites in Belgium, Brazil and 5 more
- Volunteers
- 15 people
- Sponsor
- ProQR Therapeutics
Stargardt Disease, Stargardt Macular Degeneration
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1).
- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
- Trial name
- ASTRA (NCT06942572)
- Testing
- SB-007
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- Splice Bio
Geographic Atrophy
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related…
- Trial name
- NCT06161584
- Testing
- Pegcetacoplan
- Where
- 34 sites in United States
- Volunteers
- 300 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Leber Congenital Amaurosis, Retinitis Pigmentosa
Treatment of RP and LCA by Primary RPE Transplantation
Early Phase I Study of the Safety and Preliminary Efficacy of Human primary Retinal Pigment Epithelial (HuRPE) Cells Subretinal Transplantation in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Patients
- Trial name
- NCT03566147
- Testing
- Human primary Retinal Pigment Epithelial (HuRPE) cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eyecure Therapeutics Inc.
Geographic Atrophy
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD).
- Trial name
- ArMaDa (NCT06018558)
- Testing
- OCU410
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ocugen
Brain Injuries, Traumatic
mTBI Identification and Monitoring Through Retinal Scanning
Rebion has developed a device, the Rebion trauma tool (referred to as the head and intraocular trauma tool, or "HITT"), that detects ocular fixation and alignment using a binocular retinal scan.
- Trial name
- NCT06142435
- Testing
- Head and Intraocular Trauma Tool
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rebiscan, Inc.
Geographic Atrophy
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
This multicenter study will investigate the safety, tolerability, pharmacokinetics, and immunogenicity of RO7303359 following single intravitreal (ITV) injection in participants with geographic atrophy (GA) secondary to…
- Trial name
- NCT04615325
- Testing
- RO7303359
- Where
- 12 sites in United States
- Volunteers
- 37 people
- Sponsor
- Hoffmann-La Roche
Macular Degeneration
A Long-Term Monitoring Study of the IMT-002 Patients
This is a 5-year study of patients implanted with the Implantable Miniature Telescope (IMT by Dr. Isaac Lipshitz) under Protocol IMT-002.
- Trial name
- NCT00976235
- Testing
- IMT - Implantable Miniature Telescope
- Where
- 28 sites in United States
- Volunteers
- 129 people
- Sponsor
- VisionCare, Inc.
Neovascular Age-related Macular Degeneration
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
The primary objective is to assess long-term safety and tolerability of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in patients with neovascular AMD.
- Trial name
- NCT00964795
- Testing
- Intravitreal Aflibercept Injection 2mg
- Where
- 124 sites in United States, Canada
- Volunteers
- 323 people
- Sponsor
- Regeneron Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.